392 trials
Kawasaki Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Dengue
Primary: Dengue IgG Level — 108.9; 104.0; 158.5; 143.2 RU/ml — p=< 0.01
Bladder Cancer
Primary: Number of Participants With Uptake Spot in 89Zr-girentuximab PET/CT Images — 1; 2; 3 Participants
Neoplasms
Primary: Part I: Maximum Tolerated Dose (MTD) of Ezabenlimab — NA Milligram
Renal Impairment
Primary: T1 Time — 1500 ms
Anesthesia
Primary: Insertion Depth at Initial Sensory Detection — 7.75; 4.65; 0.4; 8.55 mm
COVID - 19
Primary: Geometric Mean (GM) of Interferon-gamma (IFN-γ) Response Against the SARS-CoV-2 Virus at Baseline — 19.6; 14; 12.6 SFCs/10⁶ PBMCs
Addiction
Primary: Agitation Calmness Evaluation Scale (ACES) — 4; 4; 4; 4.07 score on a scale
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Alcohol Use Disorder
Primary: Startle Eyeblink Electromyographic (EMG) Response to Stress With an Acute Dose of Suvorexant — 0.01; .24; 0.01; -0.18 Standardized residual scores — p=.19
Prostate Cancer
Primary: Fold-change Post Flutamide Exposure — 5.860 Fold-change
Fatigue
Primary: Patient Reported Outcomes Measurement System (PROMIS) Fatigue 7a Questionnaire — -6.6; -5.4 score on a scale
Sarcopenia
Primary: Change in 6MWT — 48.3 m
Reversible Pulpitis · Ibuprofen
Primary: Change in Pain Intensity From Baseline (Pre-Operative) to Immediately During the Procedure (Day 0), Measured by the Visual Analogue Scale (VAS) — 5.05; 0.64 score on a…
Mild Traumatic Brain Injury
Primary: Blood Oxygen Level Dependent (BOLD) Brain Signal Measured Using Functional MRI. — 270; 111 voxels — p=<0.0001